These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12081616)

  • 21. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence: the regulatory career of a pharmaceutical concept.
    Carpenter D; Tobbell DA
    Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generating Model Integrated Evidence for Generic Drug Development and Assessment.
    Zhao L; Kim MJ; Zhang L; Lionberger R
    Clin Pharmacol Ther; 2019 Feb; 105(2):338-349. PubMed ID: 30414386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations for extrapolating in vivo bioequivalence data across species and routes.
    Modric S; Bermingham E; Heit M; Lainesse C; Thompson C
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():45-52. PubMed ID: 22413791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Survey of 50 years of veterinary remedy provision in the Netherlands].
    van den Bos T
    Tijdschr Diergeneeskd; 1998 Dec; 123(24):743-8. PubMed ID: 9879623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demonstrating bioequivalence using clinical endpoint studies.
    Bermingham E; Del Castillo JR; Lainesse C; Pasloske K; Radecki S
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():31-7. PubMed ID: 22413789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?
    Dupont AG; Heller F
    Acta Clin Belg; 2009; 64(5):406-14. PubMed ID: 19999388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing bioequivalence of veterinary premixes (Type A medicated articles).
    Hunter RP; Lees P; Concordet D; Toutain PL
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():53-63. PubMed ID: 22413792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AAVPT position paper regarding the evaluation of scientific manuscripts that involve the administration of compounded drugs to animals.
    Trepanier L; Pasloske K
    J Vet Pharmacol Ther; 2004 Dec; 27(6):537. PubMed ID: 15601447
    [No Abstract]   [Full Text] [Related]  

  • 35. International harmonization of bioequivalence studies and issues shared in common.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1193-200. PubMed ID: 11190204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.
    Adams WP; Poochikian G; Taylor AS; Patel RM; Burke GP; Williams RL
    J Aerosol Med; 1994; 7(2):119-34. PubMed ID: 10147277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges associated with the demonstration of bioequivalence of intramammary products in ruminants.
    Lainesse C; Gehring R; Pasloske K; Smith G; Soback S; Wagner S; Whittem T
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():65-79. PubMed ID: 22413793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine.
    Keller WC; Bataller N; Oeller DS
    J Am Vet Med Assoc; 1998 Jul; 213(2):208-11. PubMed ID: 9676589
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.